INHIBITION OF STENOSIS AT THE GRAFT/VEIN ANASTOMOSIS

Information

  • Research Project
  • 6211104
  • ApplicationId
    6211104
  • Core Project Number
    R43DK057913
  • Full Project Number
    1R43DK057913-01A1
  • Serial Number
    57913
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2000 - 24 years ago
  • Project End Date
    2/28/2003 - 21 years ago
  • Program Officer Name
    SCHERBENSKE, M. JAMES
  • Budget Start Date
    9/30/2000 - 24 years ago
  • Budget End Date
    2/28/2003 - 21 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/26/2000 - 24 years ago

INHIBITION OF STENOSIS AT THE GRAFT/VEIN ANASTOMOSIS

End-stage renal disease (ESRD) was inevitably fatal until the development of an external shunt together with the use of dialysis technology. According to the NIH, the incidence of treated ESRD in the US is rising 7.8% per year. Over 200,000 ESRD patients are presently being treated with hemodialysis through a graft/vein shunt. Current experience has shown that these grafts typically fall in 14-19 months. Clinically, most graft failures are secondary to thrombosis resulting from stenosis at the graft/vein anastomosis. Stenosis is the result of a cellular proliferation similar to that observed following other vascular interventions, including angioplasty and synthetic bypass graft placement. Similar intimal hyperplasia responses to vascular interventions (e.g. angioplasty) have been recently treated with ionizing radiation. Nearly all of the methods thus far proposed treat arterial vessels from the inside. Stenotic lesions are frequently eccentric within the vessel lumen, and proliferation is believed to be initiated in the smooth muscle cells near the adventitial layer of the vessel. It is proposed that an optimum prophylactic treatment for the threatened stenosis would deliver therapeutic levels of ionizing radiation over an extended period of time via a device that is positioned around the vessel/graft junction at the time of graft implant surgery. An external "wrap-around" source of radiation provides far greater spatial uniformity of dose in the treatment zone than an internal source. The selection of backing is important for minimizing dose to other tissue and to the physician. Only a single procedure is required to install both the graft and the wrap. PROPOSED COMMERCIAL APPLICATIONS: End-stage renal disease is treated with dialysis technology using an external shunt for access. The shunt graft frequently fails within a year due to low blood flow caused by stenosis. This proposal describes a method for inhibiting stenosis, significantly reducing revision surgeries and trauma to the patient.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IMPLANT SCIENCES CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WAKEFIELD
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01880
  • Organization District
    UNITED STATES